alpha-Neup5Ac-(2--3)-beta-D-Galp-(1--4)-[alpha-L-Fucp-(1--3)]-D-GlcpNAc has been researched along with Dermatitis* in 1 studies
1 other study(ies) available for alpha-Neup5Ac-(2--3)-beta-D-Galp-(1--4)-[alpha-L-Fucp-(1--3)]-D-GlcpNAc and Dermatitis
Article | Year |
---|---|
Therapeutic potential of a novel synthetic selectin blocker, OJ-R9188, in allergic dermatitis.
1. We investigated the ability of a newly synthesized sugar derivative, OJ-R9188, [N-(2-tetradecylhexadecanoyl)-O-(L-alpha-fucofuranosyl)-D-seryl]-L-glutamic acid 1-methylamide 5-L-arginine salt, to block binding of selectins to their ligands in vitro and inhibit the infiltration of leukocytes in vivo. 2. OJ-R9188 prevented the binding of human E-, P- and L-selectin-IgG fusion proteins to immobilized sialyl Lewis(x) (sLe(x))-pentasaccharide glycolipid, with IC(50) values of 4.3, 1.3, and 1.2 microM, respectively. 3. In a mouse model of thioglycollate-induced peritonitis, OJ-R9188 at 10 mg kg(-1), i.v. inhibited neutrophil accumulation in the peritoneal cavity. In the IgE-mediated skin reaction, OJ-R9188 at 3 and 10 mg kg(-1), i.v. significantly inhibited extravasation of neutrophils and eosinophils into the inflammatory sites and at 10 mg kg(-1), i.v. also inhibited infiltration caused by picryl chloride-induced delayed-type hypersensitivity in mice. These results suggest that OJ-R9188 may be a useful selectin blocker, with activity against human and mouse E-, P- and L-selectins in vitro and in vivo, and that blocking selectin-sLe(x) binding is a promising strategy for the treatment of allergic skin diseases. Topics: Animals; Anti-Inflammatory Agents; Binding, Competitive; Deoxyguanosine; Dermatitis; Dexamethasone; Dose-Response Relationship, Drug; E-Selectin; Free Radical Scavengers; Humans; Hypersensitivity, Delayed; Immunoglobulin G; L-Selectin; Male; Mice; Mice, Inbred BALB C; Oligosaccharides; P-Selectin; Peritonitis; Picryl Chloride; Polysaccharides; Recombinant Fusion Proteins; Selectins; Sialyl Lewis X Antigen; Thioglycolates | 2001 |